Today’s AI Top Pick: SPRO
7/20/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.
AI-ranked from a screened shortlist, with entry strategy, targets, and risks.
View the live SPRO price forecast →
SPRO is the cleanest contrarian bounce setup in the pool because it is the rare small-cap here with genuine fundamentals backing the technical thesis. Trailing PE is 6.48, forward PE just 2.36, ROE 35.12%, profit margin 27.82%, and sales YoY +93.5% — a fundamental score of 8, the highest in the entire candidate list, on a stock down ~28% in 14 days with RSI 26.37. This is not a broken biotech; it's an actually earnings-positive name that got sold off, which is exactly the profile the contrarian_bounce lens is designed to catch. Multi-timeframe agreement is exceptional and near-term skewed (which matters more than a single fat weekly print). 1h fc_short +71.03%, 4h fc_short +65.76%, 1d fc_short +20.18%, and even the weekly fc_short is +28.5%. Mid-horizon: 1h +65.96, 4h +61.2, 1d +47.77. Bullish probability is 1.0 and near_term_bullish is 1.0 — every timeframe pointing up. Position in 21-bar range is 0-4.23% (i.e., right at the bottom) and drawdown from 21-bar high is -26 to -30% across intraday TFs — not making fresh weekly lows (weekly dd -43.86 is older), which is the 'exhausted selling, not broken trend' signature we want. The kicker is the news catalyst: on July 15 Innovent licensed IBI355 rights to Spero for up to $1.1B — a massive deal for a $91M market cap company, plus a Seeking Alpha 'Buy' call on the Utebzi royalty deal. That's a concrete, funded, positive catalyst that argues the drawdown is a delayed shakeout / stale-hands rotation rather than deteriorating fundamentals. Analyst target upside is 153.2%. Compared to alternatives: IBM has a bearish weekly forecast (-15.69% long) and a nasty 'AI crash / hidden casualty' headline; ASPI just filed a shelf + 23.2M share selling stockholder prospectus (dilution overhang); RCAT/RDW are further along in their bounces; QBTS insider just sold 50k shares and has -68% weekly forecast; ILLR has unresolved Nasdaq compliance/dilution risk. SPRO is the highest-conviction, cheapest, and best-catalyzed name today.
- Micro-cap ($91M) biotech — a single trial or dilution headline can move it 20%+ intraday
- Weekly fc_long is -6.48%, so if the bounce doesn't materialize in 2-6 weeks the longer-term forecast turns neutral/negative
- Recom is 3.0 (Hold) despite the strong 153% target upside — analysts are not aggressively bullish yet
- Short float 6.69% is moderate but not a squeeze setup; needs organic demand to move
- The Innovent deal is 'up to $1.1B' in milestones — actual near-term cash contribution is likely much smaller and could disappoint
| # | Symbol | Verdict | Score | Read |
|---|---|---|---|---|
| 1 | SPRO | BUY NOW | 8.7 | Highest fundamental score in pool (8), PE 6.48 / fwdPe 2.36, all TFs bullish, and a $1.1B Innovent licensing deal just landed — best risk/reward today. |
| 2 | CRML | BUY NOW | 7.6 | Cantor Speculative Buy $18 PT, all TFs +20-74%, RSI 27.85, rare-earth policy tailwind, position 0-6% in range. |
| 3 | BCDA | BUY NOW | 7.2 | Near_term 1.0, 1d fc +51% / 1wk +143%, recom 1.0, 1767% target upside, no negative headlines. |
| 4 | OPTT | BUY NOW | 7.0 | US gov selected WAM-V drone tech, all TFs +60-120% forecasts, RSI 30.1, position 0% in range — real positive catalyst. |
| 5 | IBM | BUY PULLBACK | 6.6 | Blue-chip with PE 18.8, ROE 35.86, and near-term forecasts +20-29%, but 1wk fc_long -15.69% and 'AI hidden casualty' headline argue for patience. |
| 6 | HYPR | BUY NOW | 6.5 | RSI 26.04, all TFs positive (1h +60%, 4h +41%, 1d +22%), European Swoop MRI launch is a clean catalyst, position 0% in range. |
| 7 | GTBP | BUY PULLBACK | 6.2 | Fund score 4, recom 1.0, target upside 733%, but near_term_bullish only 0.2 and no 1wk forecast — wants intraday confirmation. |
| 8 | BESS | BUY PULLBACK | 6.1 | Fund score 6, fwdPe 2.52, weekly fc_long +99%, but near_term 0.4 and weekly already +6% — chase risk on shorter TFs. |
| 9 | ANY | BUY NOW | 6.0 | 1d fc_short +107%, 1d fc_mid +193%, DarkHorse/DRK rebrand narrative, 1665% target upside — high-variance but strong signal. |
| 10 | ATRA | BUY PULLBACK | 5.9 | Fund score 3.25, fwdPe 9.37, gross margin 96%, but 1wk already +62% off lows — near_term 0.4 says wait for pullback. |
| 11 | LTRN | BUY PULLBACK | 5.7 | Fund score 1.5, recom 1.0, target upside 823%, ZetaOmics launch is a soft catalyst; forecasts modest (+8-25%). |
| 12 | CALC | BUY PULLBACK | 5.6 | 1d fc_short +197%, FDA cleared Auxora trial continuation, but recent $49M PIPE is dilution overhang. |
| 13 | INV | BUY PULLBACK | 5.5 | All TFs positive (1h fc +89%, 1d +30%), recom 1.0, but PS 86.61 and profit margin -5226% make it purely a bounce trade. |
| 14 | FRSX | BUY PULLBACK | 5.4 | Near_term 1.0, 1d fc_long +87.8%, but tiny $7M cap and no institutional ownership (0.1%) makes it a lottery ticket. |
| 15 | BTCT | WAIT | 5.2 | All TFs positive (+38-86%) but recent private placement (dilution) and 'Why Is BTCT Falling' headline weigh on the setup. |
| 16 | GRRR | WAIT | 5.1 | 1wk fc +56-88% and 'undervalued' commentary, but $125M convertible note just priced (dilution) triggered the -32% drop. |
| 17 | IONQ | WAIT | 5.0 | Salient YoY +334%, but PS 69.4, 1wk fc_long -22%, 'above fair value' analyst note, and 1h position already at 50% of range — the easy bounce is done. |
| 18 | TROLL-USD | WAIT | 4.9 | 1h/4h forecasts +30-153%, but 1d forecasts -98% is a major red flag — model disagrees across TFs. |
| 19 | LUCY | WAIT | 4.8 | Claude AI integration is a soft catalyst, but $5M cap and warrant exercise dilution ($3M) cap upside. |
| 20 | RDW | WAIT | 4.7 | Drone theme hot, but 1wk fc mid/long slightly negative and 1d fc_short -0.29% — the easy money already ran. |
| 21 | SST | WAIT | 4.5 | 1d fc +85-177% and 1wk +200%, but near_term_bullish 0.2, tiny $17M cap, sales -31% YoY — waiting for confirmation. |
| 22 | CWD | WAIT | 4.3 | 1wk fc_mid +582%, but debtEq 103.35, roe -15,216%, and sales -51% — fundamentals are a wreck. |
| 23 | ASPI | AVOID | 4.0 | Strong forecasts undercut by fresh shelf registration and 23.2M share selling stockholder prospectus — dilution overhang is real. |
| 24 | LESL | AVOID | 3.9 | 1wk fc_long +1307% is noise from a tiny base; target upside only 4.2%, negative StockStory writeup, -67% YoY — broken trend. |
| 25 | QBTS | AVOID | 3.8 | CEO just sold 50k+ shares, 1wk fc_long -68%, PS 498, and Simply Wall St says 'too expensive after 7x run' — top-heavy. |
| 26 | RCAT | AVOID | 3.7 | Made a fresh 2-month low on July 13; forecasts are modest and the drone narrative already got its bounce elsewhere (ONDS/AVAV). |
| 27 | ILLR | AVOID | 3.2 | Nasdaq is not recognizing the omnibus share authorization — active compliance/dilution risk explicitly flagged in headlines. |
| 28 | BIRD | AVOID | 3.0 | 1wk fc all negative (-25 to -27%), fund score -3, recent rebrand + CEO change is post-catalyst — bounce already happened. |
| 29 | DSY | AVOID | 2.5 | ROE -9117%, profit margin -1800%, no forecast data provided, no target upside — nothing to work with. |
| 30 | RXRX | AVOID | 2.3 | Worst fundamental score in pool (-3.5), PS 23.5, profit margin -843%, short float 36.6% — this is a broken trend, not a bounce setup. |
Get AI top picks & forecasts on any stock
K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord